M Pharmaceutical (OTCQB:MPHMF; CSE:MQ) announced findings from the third of three proprietary pilot studies related to the recently acquired Chelatexx technology, or the company’s C-103 project.
The third study, conducted in India, found that C-103 was over 97% effective in eliminating the GI adverse events associated with orlistat.
The finding is consistent with the first and second of the three pilot study findings, which both found C-103 was over 98% effective in eliminating the GI adverse events associated with orlistat.
C-103 is a novel formulation of orlistat, which is patented until 2030 in the U.S. Orlistat is FDA-approved for weight management and sold by Roche as Xenical by prescription and by GlaxoSmithKline over-the-counter as alli.
Orlistat is the best-selling weight loss medication of all time with peak sales of more than $900-million in 2007, but its use is limited by socially unacceptable bowel-related side effects.
“M Pharma’s review and assessment of these three studies fully supports our business objective to advance toward the commercialization of C-103, with the goal of helping millions of people to reach and maintain a healthy weight,” president and CEO, Brian Keane, said in a statement.